Filing Details

Accession Number:
0001209191-23-050033
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-19 17:50:48
Reporting Period:
2023-09-15
Accepted Time:
2023-09-19 17:50:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX Biological Products, (No Disgnostic Substances) (2836) 464099738
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1856081 Shafique Virani C/O Recursion Pharmaceuticals
41 S. Rio Grande Street
Salt Lake City UT 84101
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2023-09-15 18,000 $2.22 158,351 No 4 M Direct
Class A Common Stock Disposition 2023-09-15 18,000 $8.66 140,351 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (Right to Buy) Disposition 2023-09-15 18,000 $0.00 18,000 $2.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
433,469 2030-03-03 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Class A Common Stock Stock Option (Right to Buy) $8.55 2033-02-01 0 212,507 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2032-02-04 0 80,450 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2022-02-04 2032-02-04 0 5,436 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2033-02-01 0 212,507 Direct
2032-02-04 0 80,450 Direct
2032-02-04 0 5,436 Direct
Footnotes
  1. Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
  2. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  3. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
  4. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.